InsiderTrades

Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001819790-25-000045 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-18 2025-03-15 TARS Whitfield Dianne C. CHRO M - OptEx — +18.9K 53.1K +55% —
DM 2025-03-18 2025-03-15 TARS Whitfield Dianne C. CHRO M - OptEx $0.00 -18.9K 14.5K -57% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-15 M A 18,885 — 53,066 D — — (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
2 Derivative Restricted Stock Units 2025-03-15 M D 4,462 $0.00 4,463 D — · — to — 4,462 Common Stock (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F3) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.
3 Derivative Restricted Stock Units 2025-03-15 M D 7,175 $0.00 21,527 D — · — to — 7,175 Common Stock (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F5) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
4 Derivative Restricted Stock Units 2025-03-15 M D 7,248 $0.00 14,497 D — · — to — 7,248 Common Stock (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F4) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.